Working… Menu

A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04038359
Recruitment Status : Recruiting
First Posted : July 30, 2019
Last Update Posted : October 3, 2019
Information provided by (Responsible Party):
Verastem, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 30, 2022
Estimated Study Completion Date : July 29, 2024